Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases
Experimental Dermatology · 2024
DOI: 10.1111/exd.15091 ↗At a glance
Übersichtsarbeit in Experimental Dermatology, 2024. Written by Alec Sevilla and 1 co-authors. Institution: Department of Dermatology, New York Medical College, New York, New York, USA. Major MEDLINE topics: Stem Cell Factor, Melanocytes, Mast Cells, Mastocytosis. Cited 5 times so far (Crossref); 200 references.
Abstract (original language)
KIT ligand and its associated receptor KIT serve as a master regulatory system for both melanocytes and mast cells controlling survival, migration, proliferation and activation. Blockade of this pathway results in cell depletion, while overactivation leads to mastocytosis or melanoma. Expression defects are associated with pigmentary and mast cell disorders. KIT ligand regulation is complex but efficient targeting of this system would be of significant benefit to those suffering from melanocytic or mast cell disorders. Herein, we review the known associations of this pathway with cutaneous diseases and the regulators of this system both in skin and in the more well‐studied germ cell system. Exogenous agents modulating this pathway will also be presented. Ultimately, we will review potential therapeutic opportunities to help our patients with melanocytic and mast cell disease processes potentially including vitiligo, hair greying, melasma, urticaria, mastocytosis and melanoma.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, New York Medical College, New York, New York, USA.
- Department of Internal Medicine, Lakeland Regional Health, Lakeland, Florida, USA.
- Department of Dermatology and Cutaneous Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
ORCID profiles: Alec Sevilla
Cite
APA
Sevilla, A., & Grichnik, J. (2024). Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology. https://doi.org/10.1111/exd.15091
Vancouver
Sevilla A, Grichnik J. Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology. 2024. doi:10.1111/exd.15091
BibTeX
@article{Sevilla2024,
author = {Sevilla, Alec and Grichnik, James},
title = {Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15091}
}
EUVIMED